Prolonged coagulation instability is associated with a higher-dose regimen of tissue-type plasminogen activator in patients with acute myocardial infarction.
Andreotti
F
F
Cardiovascular Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
Kluft
C
C
Davies
G J
GJ
Hackett
D R
DR
Prevost
R
R
Maseri
A
A
D000990:Antithrombin III / Q000032:analysis; D001241:Aspirin / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D004110:Diltiazem / Q000627:therapeutic use; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D005342:Fibrinolysis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D010447:Peptide Hydrolases / Q000032:analysis; D011994:Recombinant Proteins / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D015415:Biomarkers; D011994:Recombinant Proteins; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D006493:Heparin; D010447:Peptide Hydrolases; D010959:Tissue Plasminogen Activator; D004110:Diltiazem; D001241:Aspirin